|
Samchully Pharmaceutical specializes in nucleosides and their derivatives and has become one of the largest
API manufacturers in the world. Samchully is actively securing its own new drug development pipeline through
project collaboration and in-licensing of high-potential drug candidates and/or technologies, especially in
nucleosides, non-nucleosides, gene-therapeutic oligonucleotide drugs, and biopharmaceuticals for anti-virals and
anti-cancers.
As of January 2008, the Joint United Nations Program on HIV/AIDS (UNAIDS) and the World Health
Organization (WHO) estimated that AIDS killed more than 30 million people since it was first recognized in 1981,
making it one of the most destructive epidemics in recorded history.
With regard to HIV/AIDS drugs, Samchully Pharmaceutical has had long working relationships with several
major pharmaceutical companies. Thanks to the customer’s confidence in the Korean company’ production
system, Samchully Pharmaceutical has secured an exclusive supply position for several pipelines. These major
products include Zidovudine and Stavudine.
|
